-
Puma Biotechnology Inc.’s surging valuation is stoking optimism its chief executive officer will succeed in selling his second straight drug developer to a major pharmaceutical company.
-
Reckitt Benckiser Plc, the maker of Nurofen painkillers, entered a $482 million deal with pharmaceutical maker Bristol-Myers Squibb Co. to license a number of Latin American over-the-counter healthcare remedies as it expands its presence in emerging markets.
-
Bristol-Myers Squibb Co.’s “string of pearls” strategy of acquisitions and partnerships will remain in place even after the loss of the executive who was most responsible for implementing it, the drugmaker said.
-
Bristol-Myers Squibb Co.’s fourth- quarter earnings beat analysts’ estimates after the company took a tax benefit from a hepatitis C drug that failed last year.
-
At a time when more than one in five U.S. insider-trading cases involve health-care stocks, the industry’s companies say their policies designed to prevent abuse are sufficient -- or they refuse to publicly discuss the issue at all.
-
Bristol-Myers Squibb Co. is the only U.S. drugmaker among the top 12 to decline in trading this year, and investors and analysts say they don’t expect a comeback in 2012 because of drug pipeline setbacks.
-
Bristol-Myers Squibb Co. is planning to sell an experimental migraine drug that’s in mid-stage testing because the medicine isn’t a good fit for its business, according to a person familiar with the matter.
-
After helping Bristol-Myers Squibb Co. acquire new drugs in a bid to offset the expected loss of revenue from its top-selling blood thinner Plavix, Teva Pharmaceutical Industries Ltd.’s chief executive officer- designate Jeremy Levin faces the same task at the Israeli drugmaker.
-
After helping Bristol-Myers Squibb Co. find new drugs to help offset the expected loss of revenue from its top-selling blood thinner Plavix, Teva Pharmaceutical Industries Ltd.’s chief executive officer-designate Jeremy Levin faces the same task at the Israeli drugmaker.
-
Amylin Pharmaceuticals Inc., maker of the diabetes drug Bydureon, may draw bids from other suitors after rejecting a $3.5 billion unsolicited takeover offer from Bristol-Myers Squibb Co. earlier this year.
Rate this Page